Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
about
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapyCombination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsApproaches to modernize the combination drug development paradigmChallenges of Pancreatic Cancer.From bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentImaging in pancreatic disease.Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.Targeting the cancer kinome through polypharmacology.The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongLenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.ZEPHYR: failure of a "spring wind" in lung cancer.Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitorsNew antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyondIntegrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.Development of recombinant human polyclonal antibodies for the treatment of complex human diseases.Biological therapy update in colorectal cancer.Current role of antibody therapy in patients with metastatic colorectal cancer.A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activityAntitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinomaRationale for combining biotherapy in the treatment of advanced colon cancer.Treatment in advanced colorectal cancer: what, when and how?Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.Palliative treatment of unresectable metastatic colorectal cancer.Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancerTyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors.Emerging antibody combinations in oncology.Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis.Targeting the VEGF signaling pathway in cancer therapy.Panitumumab: a summary of clinical development in colorectal cancer and future directions.New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment.Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.
P2860
Q26745418-34134F5B-B440-4B7A-9ADE-7C14C50D434CQ26746067-905D3774-169A-489A-ADE0-5BAE2F51AF35Q28072074-D04ED1F1-359F-485F-89B9-A2F3CB1C842BQ28080671-59AAD087-2998-41F1-9D33-F507E9E6AFCCQ28533949-0A2A6B8B-9B07-4B15-8ABF-44FD7B6392B4Q30275458-2D80E477-9E55-4025-8F64-9B59B051BFD0Q30358961-5319E660-61C3-40CB-88CE-3264BF72163DQ33457195-4EC97B34-ADE2-4611-85FB-79EDBDED2138Q33893019-365EFC3E-0C9E-4632-A4C1-288EF52933B3Q34039015-E46E241E-A4C4-48DF-9B0A-FD2D3FB841E8Q34144848-38092FCA-3D30-486B-A983-806763B08418Q34497997-2F00B128-FA6B-45CE-99AD-23B07810880AQ34765380-296DAE32-1A47-4E9A-AA55-1EE9A48477DCQ34972161-5BA2CBB0-C7C4-42F0-9A42-3DD8C9C3E671Q35011409-4F956F94-AF9A-415D-87D1-5C7667E8C99CQ35200470-91BFF789-303B-4B00-AD0C-461EF3883BFBQ35212644-CFAC5FE7-2481-42B9-B06D-84244A2DA2D1Q35660763-6B4B38EA-BCAA-4AE9-8936-33276CF19042Q36175239-75878EE3-6B84-492C-9B6F-10912DFAC0B4Q36569741-AD53E4E2-3615-4078-96F9-8F56FE21CAB3Q36764932-12058252-1AB1-4A34-A639-FE317DD34D22Q36832121-24AD5F26-7077-4A1F-A441-07771577780DQ36844361-EA51DD6D-CF77-4A4D-A021-5F974FA0CC65Q36909227-931052D4-1705-4A3F-ABF2-3A286217809AQ37077828-4A099D72-E200-4EDE-B4BF-4389079796EEQ37225720-CA6147FD-0306-473D-B6CF-119605AB4032Q37346912-EA02C443-B9FC-41C8-9FD9-78B3762B133CQ37430771-577EFAB2-C4B6-4752-9357-1B7A69AEE3E3Q37468539-611CC29B-52C4-4470-8F62-50FEF3778629Q37650308-D97FFB62-D74A-45A4-9D25-16C7A9A3FA0FQ37790985-38559E32-BFD2-48FA-BEE5-69CD19357C3FQ37818251-CCE5A276-9033-4460-9C36-CA20CF1136EAQ37821836-A075E219-9238-46FA-9098-AC902AA47A72Q37893414-3E7F62AD-CE70-4261-AFAD-3B5A23CF14B2Q37900923-DB445AFF-CD14-4475-909A-700A3DE25654Q37975243-5DE18E4C-9A19-408D-9BDD-2F022D35508BQ38003666-CBD4C698-2AFF-4EB6-BA3F-45A0FB64D09CQ38014533-18D8A4CA-0A5B-4719-A72A-B12B8F54D647Q38171330-3CD2F681-7062-4F3B-ABA6-790E38D30110Q38684978-0EA512B7-EA1C-4133-84A4-C4F08570A816
P2860
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Synergistic antitumor effects ...... r receptor-2 targeted therapy.
@en
type
label
Synergistic antitumor effects ...... r receptor-2 targeted therapy.
@en
prefLabel
Synergistic antitumor effects ...... r receptor-2 targeted therapy.
@en
P2093
P1476
Synergistic antitumor effects ...... r receptor-2 targeted therapy.
@en
P2093
Daniel J Hicklin
Dhanvanthri S Deevi
Erik Corcoran
Francine E Carrick
Huiling Li
James R Tonra
P304
P356
10.1158/1078-0432.CCR-05-1682
P407
P433
P577
2006-04-01T00:00:00Z